Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideo
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
The National Institutes of Health launched a Phase II clinical trial in October of HVTN 205, an experimental preventive HIV vaccine that uses synthetic genes from strains A, B, and C of the virus, which account for 85% of the world's HIV cases. __________ Merck announced plans in September to double the enrollment in its clinical trial of MRKAd5--a preventive and therapeutic experimental HIV vaccine--after early study data showed that the vaccine boosted participants' CD4 cells to 50 to 100 times their baseline number. The vaccine uses a common cold virus to deliver key HIV genes into the body to stimulate the immune system to attack HIV.
From our Sponsors
Most Popular
Plus: Featured Video